High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Project description

Tumour bioprinting: the future of drug discovery

Current approaches for studying tumour biology and for performing drug screening rely on 2D cell cultures and animal models. However, they do not accurately reflect the size, heterogeneity and vascularity of the human tumour microenvironment. Scientists of the EU-funded TUMOURPRINT project are working on a disruptive bioprinting technology capable of fabricating tissue models with high fidelity. The technology uses live cells in combination with specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development. Results are expected to revolutionise the drug development processes by offering cancer models in an automated, precise and reproducible way.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• engineering and technology › electrical engineering, electronic engineering, information engineering › electronic engineering › robotics
• medical and health sciences › clinical medicine › oncology

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-2
See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

CELLINK AB

Address

Arvid Wallgrens Backe 20
413 46 Goteborg
Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 2 450 327,25